This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altimmune Stock Up More Than 25% in a Month: Here's Why
by Zacks Equity Research
ALT's recent progress related to the development of the lead product candidate, pemvidutide, for treating obesity and MASH is aiding the stock.
Mirum Shares Surge More Than 90% in 6 Months: Here's Why
by Zacks Equity Research
MIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company's efforts to build its pipeline beyond Livmarli also hold promise.
GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo
by Zacks Equity Research
The European Commission approves fully liquid presentation of GSK's meningococcal vaccine, Menveo, to protect against invasive meningococcal disease.
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 112.8% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma
by Zacks Equity Research
The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
New Strong Buy Stocks for November 26th
by Zacks Equity Research
ZIM, MNDY, RSI, IMCR and ULS have been added to the Zacks Rank #1 (Strong Buy) List on November 26, 2024.
Corcept Shares Rise More Than 60% in Three Months: Here's Why
by Zacks Equity Research
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushing's syndrome will be filed shortly.
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
by Zacks Equity Research
Puma Biotechnology starts the phase II ALISCA-Breast1 study on alisertib for treating hormone receptor-positive, HER2-negative metastatic breast cancer.
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
by Zacks Equity Research
Sage Therapeutics' pipeline setbacks continue as the phase II DIMENSION study on dalzanemdor for treating Huntington's disease fails to meet the primary goal.
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
by Zacks Equity Research
Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
by Zacks Equity Research
INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
by Zacks Equity Research
The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
by Zacks Equity Research
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant pleural mesothelioma.
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
by Zacks Equity Research
The European Commission approves ABBV's Elahere for the treatment of platinum-resistant ovarian cancer.
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative pipeline is in focus.
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
by Zacks Equity Research
SWTX reports mixed third-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised
by Zacks Equity Research
MIRM's third-quarter 2024 earnings and revenues surpass estimates. The company increases revenue guidance for 2024. Stock rises in pre-market.
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus
by Zacks Equity Research
RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up
by Zacks Equity Research
Puma Biotechnology beats third-quarter 2024 estimates for both the top and the bottom lines. The company updates its 2024 financial guidance. Stock rallies.
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 112.6% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immunocore (IMCR) Upgraded to Buy: Here's Why
by Zacks Equity Research
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
by Zacks Equity Research
Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
by Zacks Equity Research
Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology have been highlighted in this Industry Outlook article.
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat
by Zacks Equity Research
Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.
5 Biotech Stocks to Consider for Your Portfolio in 2024
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.